by administrator | Apr 12, 2016 | Appili Therapeutics, News
See original post here HALIFAX, Nova Scotia – April 12, 2016 – Appili Therapeutics Inc., an anti-infective pharmaceutical development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ATI-1501, a...